Change in stiffness and effect of orientation in degrading polylactide films

The degradation pattern of the synthetic absorbable polyester is thought to occur from the center of the material outward, and the bulk degradation is therefore attributed largely to the chemical composition of the material. It was hypothesized that this pattern might be altered by changing the morphology of the material, i.e., by introducing molecular orientation into the system. A new solid state uniaxial orientation (SS-UO) process was used to orient two types of lactide polymer films. The films were exposed to a phosphate buffered solution, then chemically, mechanically, and visually analyzed after predetermined times. This paper explores the results of flexural testing which will be later correlated with microscopic degradation events, as part of the larger degradation study. The results show that, while orientation does not have an overall significant effect on the flexural modulus, there is a significant material/orientation interaction.     

In‐line mixing for production of citric acid by Candida lipolytica grown on n‐paraffins

This study reports on the effects of internal fermenter and external in‐line agitation and fed‐batch mode of operation on citric acid production from Candida lipolytica using n‐paraffin as the carbon source. An optimum range of fermenter agitation speeds in the range 800–1000 rpm corresponding to Reynolds numbers of 50433–62947 (based on initial batch conditions) seemed to give the best balance between substrate utilization for biomass growth and citric acid production. Proof of concept evidence is presented that indicates that an external in‐line agitator could be used in place of high speed internal agitation to increase citric acid production. However, more work is required to optimize the external agitator concept. Application of multiple fed‐batch feedings can be used to extend the batch fermentation and increase final citric acid concentrations and product yield. Experiments were conducted implementing a three‐cycle fed‐batch process which increased overall citric acid yields to 0.8–1.0 g citric acid g^?1 n‐paraffin, approximately 200% improvement from those found in the normal batch process. The three‐cycle fed‐batch mode of operation also increased the final citric acid concentration to 42 g dm^?3 from about 6 g dm^?3 for normal batch operation. Increased citric acid concentrations in three‐cycle fed‐batch mode was achieved at longer fermentation times. Copyright © 2004 Society of Chemical Industry     

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

Fas ligand (FasL) is produced by activated T cells and natural killer cells and it induces apoptosis (programmed cell death) in target cells through the death receptor Fas/Apol/CD95. One important role of FasL and Fas is to mediate immune-cytotoxic killing of cells that are potentially harmful to the organism, such as virus-infected or tumour cells. Here we report the discovery of a soluble decoy receptor, termed decoy receptor 3 (DcR3), that binds to FasL and inhibits FasL-induced apoptosis. The DcR3 gene was amplified in about half of 35 primary lung and colon tumours studied, and DcR3 messenger RNA was expressed in malignant tissue. Thus, certain tumours may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL.     

Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates

Radiolabelled antisense oligodeoxynucleotides have been used for in vivo biokinetic studies in AIDS and cancer patients. The therapeutic possibilities are still unknown and the major question in therapeutic use of radio-oligonucleotide is the optimal source of radiation. We studied the pharmacokinetics and in vivo tissue distribution for oligodeoxynucleotide phosphorothioates by using the data from three different radionuclides: sulphur-35 (t1/2 = 87.4 days, maximum beta-energy = 167 keV), phosphorus-33 (t1/2 = 24.4 days, maximum beta-energy = 250 keV) and phosphorus-32 (t1/2 = 14.3 days, maximum beta-energy = 2270 keV). The absorbed doses of 32P-, 33P- and 35S-labelled oligonucleotides were estimated using the published biodistribution data for several oligonucleotides in two animal models for both tumour xenografts and AIDS. The local energy absorption of 33P turned out to be higher than that of 32P if the mass was smaller than approximately 300 micrograms, and the local absorption of 35S was higher than that of 32P when the mass was <80 micrograms. In a mouse tumour xenograft model an i.v. injected activity seemed to achieve sufficient radiation doses in the tumour: in a 1 g tumour 4.9 Gy for 32P, 5.1 Gy for 33P and 5.5 Gy for 35S were calculated when the kidney dose was kept as 5 Gy. In the same model in smaller tumours the doses were for a 1 mg tumour 0.73 Gy (32P), 5.1 Gy (33P) and 5.5 Gy (35S), and for a 1 microgram tumour 0.08 Gy (32P), 3.1 Gy (33P) and 3.9 Gy (35S). Thus, 33P and 35S have more beneficial radiotherapeutic characteristics than 32P. Relative advantage factors (33P and 35S versus 32P) for kidney and liver doses using these nuclides varied from 0.997 to 1.001 for a 1 g tumour and there was no difference in the radiation dose to normal organs. Therefore, we conclude that in oligonucleotide radiotherapy tumours >1 g should be treated with 32P, whereas smaller tumours should be treated with 33P or 35S. There is no significant difference between 33P and 35S, and either radionuclide could be selected according to labelling properties.